ME RESOURCE CORP.

Condensed Interim Financial Statements

Three and Nine months ended September 30, 2021 and 2020

Unaudited - Expressed in Canadian Dollars

ME Resource Corp. Condensed Interim Statements of Financial Position (Unaudited - Expressed in Canadian Dollars)

	September 30, 2021	December 31, 2020
	\$	\$
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (Note 4)	472,025	382,413
Note payable (Note 5)	-	57,063
Due to related parties (Note 6)	1,550,723	1,370,723
	2,022,748	1,810,199
SHAREHOLDERS' DEFICIENCY		
Share capital (Note 4)	5,861,105	5,861,105
Reserves	1,745,278	1,745,278
Deficit	(9,629,131)	(9,416,582)
	(2,022,748)	(1,810,199)
Total shareholders' deficiency and liabilities		-

Note 1: Nature and operation and going concern

Authorized for issuance by the Board of Directors

<u>/s/ Navchand Jagpal</u> <u>/s/Ravinder Kang</u> <u>Director</u> <u>Director</u>

ME Resource Corp.

Condensed Interim Statements of Loss and Comprehensive Loss
(Unaudited - Expressed in Canadian Dollars)

	Three months September 30,		Nine months September 30,		
	2021 2020		2021	2020	
	\$	\$	\$	\$	
Expenses					
Consulting and management (Note 6)	60,000	60,000	180,000	180,000	
Filing fees	2,912	11,538	18,498	21,294	
Interest expense	-	1,377	370	3,294	
Professional fees	4,500	3,000	13,680	11,000	
Loss and comprehensive loss	(67,412)	(75,915)	(212,548)	(215,588)	
loss per share – basic and diluted	(0.00)	(0.00)	(0.00)	(0.00)	
Weighted average number of outstanding common shares, basic and diluted	63,671,935	63,671,935	63,671,935	63,671,935	

ME Resource Corp. Condensed Interim Statements of Cash Flows (Unaudited - Expressed in Canadian Dollars)

Nine months ended September 30,	2021	2020
	\$	\$
OPERATING ACTIVITIES		
Loss for the period	(212,548)	(215,588)
Items not involve cash		
Accrued consulting fees	180,000	180,000
Changes in non-cash working capital items:		
- accounts payable and accrued liabilities	89,611	14,551
Cash provided by operating activities	57,063	(21,037)
FINANCING ACTIVITIES		
Repayment of note payable	(57,063)	-
Proceeds from note payable	-	21,037
Cash used in financing activities	(57,063)	21,037
Net cash inflow	-	-
Cash, beginning of period	-	_
Cash, end of period		

ME Resources Corp.

Condensed Interim Statements of Changes in Deficiency
(Unaudited - Expressed in Canadian Dollars)

	Share ca	pital]	Reserves			
	Number of shares	Amount	Stock- option \$	Loan \$	Warrant \$	Deficit \$	Total \$
Balance, December 31, 2019	63,671,935	5,861,105	1,694,396	5,121	45,761	(9,132,557)	(1,526,174)
Loss for the period		-		-		(215,588)	(215,588)
Balance, September 30,2020	63,671,935	5,861,105	1,694,396	5,121	45,761	(9,348,145)	(1,741,762)
Balance, December 31, 2020	63,671,935	5,861,105	1,694,396	5,121	45,761	(9,416,583)	(1,810,200)
Loss for the period	-	-	-	-	-	(212,548)	(212,548)
Balance, September 30, 2021	63,671,935	5,861,105 -	1,694,396	5,121	45,761	(9,629,131)	(2,022,748)

Notes to the Condensed Interim Financial Statements Three and Nine Months Ended September 30, 2021, and 2020 (Unaudited - Expressed in Canadian Dollars)

1. NATURE AND CONTINUANCE OF OPERATIONS

ME Resource Corp., (the "Company" or "MEC") was incorporated under the Business Corporation Act (British Columbia) on October 16, 2009. The Company's shares are traded on the Canadian Securities Exchange ("CSE") under the symbol MEC. The Company's head and registered office address is 204 – 6321 King George Blvd. Surrey, B.C. V3X 1G1

The Company is currently seeking new business opportunities (Note 3)

These condensed interim financial statements have been prepared using International Financial Reporting Standards applicable to a going concern, which assume that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. Different bases of measurement may be appropriate if the Company is not expected to continue operations for the foreseeable future. The Company's continuation as a going concern is dependent whether the Company can develop an economically viable business and generate funds there from and/or raise equity capital to meet current and future obligations. The Company has not yet achieved profitable operations and expects to incur further losses in the development of its business. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs over the next twelve months with loans and/or private placement of common shares. Should the Company be unable to continue as going concern, the net realizable value of its assets may be materially less than the amounts on its statements of financial position.

The recent outbreak of the coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Conditions surrounding the coronavirus continue to rapidly evolve and government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company's business activities. The extent to which the coronavirus may impact the Company's business activities will depend on future developments, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time.

2. BASIC OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Statement of compliance

These condensed interim financial statements together with the comparative figures herein have been prepared in accordance with International Accounting Standards ("IAS") 34 "Interim Financial Reporting" ("IAS 34") using accounting policies consistent with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee.

These condensed interim financial statements do not include all the information required of a full annual financial report and is intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that these condensed interim financial statements be read in conjunction with the most recent audited annual financial statements of the Company for its recent year ended December 31, 2020.

These condensed interim financial statements were authorized for issue by the Board of Directors on November 18, 2021.

Notes to the Condensed Interim Financial Statements Three and Nine Months Ended September 30, 2020, and 2019 (Unaudited - Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued)

Basis of measurement

These condensed interim financial statements have been prepared on an accrual basis and are based on historical costs, except for certain financial instruments which are measured at fair value. The financial statements are presented in Canadian dollars, the functional currency of the Company. The preparation of financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for financial instruments and the recognition and measurement of deferred tax assets.

Significant judgments

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgment in applying the Company's financial statements include:

- the classification of financial instruments;
- the assessment of the Company's ability to continue as a going concern; and
- the determination of the recoverability of the Company's deferred tax assets

Adoption of new accounting policies

The Company has not adopted new accounting policies since its recent year ended December 31, 2020.

3. PROPOSED BUSINESS COMBINATION

In March 2021, the Company entered into a definitive agreement with Albert Labs Inc ("Albert Labs"), a private company in the business of clinical research and drug development, to complete a reverse-take-over arrangement (the "Transaction" of "RTO"), whereby the resulting issuer of the RTO intend to secure a listing on the CSE pursuant to approval from the regulatory.

Upon completion of the this proposed Transaction, the resulting issuer will continue to carry on the business of Albert Labs as currently constituted, under the new name "Albert Labs Inc." or such other name as may be approved by the CSE.

The definitive agreement has been approved by the directors of MEC and Albert Labs.

Before the completion of the Transaction, the Company will consolidate its common shares on a 10-1 basis; and plan to issue not more than 3,273,942 post-consolidated common shares to settle certain payables to creditors and related parties at a deemed price of \$0.50 per share.

Upon the completion of the Transaction, the Company will issue 38,663,700 post-consolidated common shares in exchange all the outstanding shares of the Albert Labs.

As at the date of this report, this proposed Transaction is not completed pending approval from regulatory.

Notes to the Condensed Interim Financial Statements Three and Nine Months Ended September 30, 2020, and 2019 (Unaudited - Expressed in Canadian Dollars)

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	September 30, 2021	December 31, 2020	
	\$	\$	
Trade payables	332,727	343,954	
Salaries payable	20,066	20,066	
Accrued liabilities	13,100	18,393	
Due to Albert Labs (Note 5)	106,132	-	
	472,025	382,413	

During the nine months ended September 30, 2021, Albert Labs advanced the Company \$106,132 to finance the Company's operations and for the repayment of certain outstanding payables. This amount owing to the Albert Labs is unsecured, payable on demand, and non-interest bearing,

5. NOTE PAYABLE

On March 31, 2019, the Company issued an unsecured, note payable to Moonstruck Capital which promises to repay any advances Moonstruck made to cover the Company's expenses. The note carries interest at 10% per annum based on the date of the advances and principal and interest is due on October 31, 2020. The lender further advanced the Company \$17,821 on June 15, 2020, with the same terms of repayment.

The terms of repayment changed to on-demand after October 31, 2020, and subsequently to the year ended December 31, 2020. As of December 31, 2020, the amount of outstanding was \$50,764 with accrued interest of \$6,299, totalling \$57,063.

In March 2021, Albert Labs advanced the Company \$57,433 to fully repay the principal and accrued interest of the above promissory note. The Company recorded an interest expense of \$370 for the nine months ended September 30, 2020 (Note 4)

6. SHARE CAPITAL

Authorized share capital: An unlimited number of common shares without par value.

An unlimited number of preferred shares without par value.

Issued and outstanding: 63,671,935 common shares

During the nine months ended September 30, 2021, the Company did not issue any common shares.

Notes to the Condensed Interim Financial Statements Three and Nine Months Ended September 30, 2020, and 2019 (Unaudited - Expressed in Canadian Dollars)

6. SHARE CAPITAL (Continued)

Stock options

The Company has a stock option plan which provides that the Board of Directors of the Company may grant to directors, officers, employees, and consultants to the Company, non-transferable options to purchase common shares. The number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. The term of any options granted under the plan may not exceed 5 years. Vesting terms and conditions are established by the Board of Directors.

The Company has not issued stock options during the nine months ended September 30, 2021. the Company did not have options outstanding as of September 30, 2021, and December 31, 2020.

Stock option reserve

The stock option reserve records items recognized as stock-based compensation expense and other share-based payments until such time that the stock options or warrants are exercised, at which time the corresponding amount will be transferred to share capital.

Warrant reserve

The warrant reserve records the fair value of warrants issued until such time that they are exercised, at which time the corresponding amount will be transferred to share capital.

Loan Reserve

Recorded in the loan reserve is a discount on a loan which was issued with interest below market rates.

7. RELATED PARTY TRANSACTIONS

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers.

a) Transactions with key management personnel were as follows:

Nine months ended September 30,	2021	2020
	\$	\$
Consulting fees charged by a director	45,000	45,000
Consulting fees charged by a company related to the chief		
executive officer ("CEO")	90,000	90,000
Consulting fees charged by the chief financial officer ("CFO")	45,000	45,000
	180,000	180,000

b) Balances due to related parties:

Amounts due to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

Due to Related parties	September 30, 2021	December 31, 2020	
	\$	\$	
Directors	409,000	364,000	
Chief financial officer	364,600	319,600	
Companies related to the CEO	777,123	687,123	
	1,550,723	1,370,723	

Notes to the Condensed Interim Financial Statements Three and Nine Months Ended September 30, 2020, and 2019 (Unaudited - Expressed in Canadian Dollars)

8. FINANCIAL INSTRUMENTS

Financial Risk Management

The Company has not changed its approach in handling the financial risks since its recent year ended December 31, 2021.

Classification of financial instruments

Financial instruments included in the statement of financial position are as follows:

	September 30, 2021	December 31, 2020
	\$	\$
Amortized cost:		
Trade payables	332,727	343,954
Salaries payable	20,066	20,066
Note payable	-	57,063
Due to Albert Labs	106,132	-
Due to related party	1,550,723	1,370,723

Fair value

The Company does not have financial instruments that are measured at their fair values. Financial instruments that are not measured at their values are note receivable, trade payables, salaries payable and due to related parties. Their carrying values approximate their fair values due to their short terms to maturity.